Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2023 Earnings Conference Call May 2, 2023 8:00 AM ET
Company Participants
Helen Rubinstein - Director of Investor Relations
Barry Greene - Chief Executive Officer
Jim Doherty - Chief Development Officer
Chris Benecchi - Chief Business Officer
Kimi Iguchi - Chief Financial Officer
Laura Gault - Chief Medical Officer
Conference Call Participants
Anupam Rama - JPMorgan
Ritu Baral - PD Cowen
Yasmeen Rahimi - Piper Sandler
Jay Olson - Oppenheimer
Paul Matteis - Stifel
Sumant Kulkarni - Canaccord
Neena Bitritto-Garg - Citi
Tim Lugo - William Blair
Marc Goodman - SVB Securities
Operator
Good morning. Welcome to the Sage Therapeutics' First Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Sage's website at sagerx.com. This call is the property of Sage Therapeutics and recording, reproduction, or transmission of this call without the expressed written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.
I would now like to introduce Helen Rubinstein, Director of Investor Relations at Sage.
Helen Rubinstein
Good morning and thank you for joining Sage Therapeutics' first quarter 2023 financial results conference call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at sagerx.com, where you can find the press release related to today's call, as well as the slides that we would be reviewing today.
I'd like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional details.
We will begin the call with prepared remarks by Barry Greene, our Chief Executive Officer, who will provide an overview of our progress during the first quarter of 2023. We will also be joined by Jim Doherty, our Chief Development Officer, who will review recent progress and development activities across our program, our Chief Business Officer, Chris Benecchi, who will provide an update on our preparations for the potential launch of zuranolone in MDD and PPD, and we will then be joined Kimi Iguchi, our Chief Financial Officer, who will review the financial results from the first quarter 2023, Laura Gault, our Chief Medical Officer will be available during the Q&A portion of the call.